key: cord-0884586-o5asv536
authors: Hottz, Eugenio D.; Martins-Gonçalves, Remy; Palhinha, Lohanna; Azevedo-Quintanilha, Isaclaudia G.; de Campos, Mariana M.; Sacramento, Carolina Q.; Temerozo, Jairo R.; Soares, Vinicius Cardoso; Dias, Suelen S. Gomes; Teixeira, Lívia; Castro, Ícaro; Righy, Cάssia; Souza, Thiago Moreno L.; Kurtz, Pedro; Andrade, Bruno B.; Nakaya, Helder I.; Monteiro, Robson Q.; Bozza, Fernando A.; Bozza, Patrícia T.
title: Platelet-monocyte interaction amplifies thromboinflammation through tissue factor signaling in COVID-19
date: 2022-04-18
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021006680
sha: 51e28d472615809a7f444dd0e146ada4acdd3158
doc_id: 884586
cord_uid: o5asv536

Accumulating evidence into the pathogenesis of COVID-19 highlight a hypercoagulability state with high risk of life-threatening thromboembolic complications. However, the mechanisms of hypercoagulability and their link to hyperinflammation remain poorly understood. Here we investigate functions and mechanisms of platelet activation and platelet-monocyte interactions in inflammatory amplification during SARS-CoV2 infection. We used a combination of immunophenotyping, single cell analysis, functional assays and pharmacological approaches to gain insights on mechanisms. Critically ill COVID-19 patients exhibited increased platelet-monocyte aggregates formation. We identified a subset of inflammatory monocytes presenting high CD16 and low HLA-DR expression as the subset mainly interacting with platelets during severe COVID-19. Single cell RNAseq analysis indicated enhanced fibrinogen receptor Mac-1 in monocytes from severe COVID-19 patients. Monocytes from severe COVID-19 patients displayed increased platelet binding and hyperresponsiveness to P-selectin and fibrinogen with respect to TFN-α and IL-1β secretion. Platelets were able to orchestrate monocyte responses driving TF expression, inflammatory activation and inflammatory cytokines secretion in SARS-CoV-2 infection. Platelet-monocyte interactions ex-vivo and in SARS-CoV-2 infection model in vitro reciprocally activated monocytes and platelets, inducing the heightened secretion of a wide panel of inflammatory mediators. We identified platelet adhesion as a primary signaling mechanism inducing mediator secretion and TF expression, while TF signaling played major roles in amplifying inflammation by inducing proinflammatory cytokines, especially TNF-α and IL-1β. Our data identify platelet-induced TF expression and activity at the crossroad of coagulation and inflammation in severe COVID-19.

Hypercoagulability is central in pathophysiology and also a significant determinant of 90 mortality in COVID-19 patients [1] [2] [3] [4] . Pulmonary and extrapulmonary microvascular 91 thrombosis is associated with multiorgan failure 5-7 occurring more frequently in 19 than in influenza pneumonia 7, 8 . While heparin treatment may be beneficial 9 , 93 persistent hypercoagulability and thromboinflammatory tissue damage have been 94 reported despite prophylactic anticoagulation 5,10,11 . Markers of coagulation and 95 inflammation, including D-dimers, TNF-α and IL-6 are early predictors of respiratory 96 distress and mortality during COVID-19 [12] [13] [14] [15] [16] . Overwhelming inflammatory activation 97 ("cytokine storm") may both sustain and be amplified by hypercoagulability 17, 18 . 98

Nevertheless, the mechanisms of hypercoagulability in COVID-19 patients and how it is 99 linked to hyperinflammation are still to be determined. 100

Platelets are blood cells classically known by their roles in thrombosis and 101 hemostasis 19 . Beyond their hemostatic activities, platelets orchestrate inflammatory 102 response, secreting inflammatory mediators and forming heterologous aggregates with 103 leukocytes [19] [20] [21] [22] . Activated platelets adhere to leukocytes reprogramming cellular 104 functions through juxtracrine signals from P-selectin and fibrinogen-bearing integrins 23-105 25 . Severe COVID-19 evolves with platelet hyperactivity and increased platelet-106 monocyte, lymphocyte and neutrophil aggregates formation [26] [27] [28] [29] . COVID-19 post 107 mortem pathological findings show extensive areas of microvascular tissue thrombosis 108 containing platelet-neutrophil complexes and NETosis 5,6 . Intravascular and airways 109

NETosis is associated with case severity and mortality 6 , and activated platelets in 110 COVID-19 are a determinant to NET extrusion 5, 30 . We have recently shown that 111 increased platelet activation and platelet-monocyte interaction in severe induce pathologic expression of tissue factor (TF) 26 , the main trigger of coagulation 113 activation and thrombosis 31 . Interestingly, TF-expressing monocytes represent a subset 114 of inflammatory monocytes highly expressing proinflammatory cytokines in people 115 living with HIV 18 , but the participation of platelets in this monocyte subset 116 reprogramming remains unknown. Our central hypothesis is that platelet-induced 117 procoagulant and proinflammatory signaling in monocytes are linked, amplifying 118 inflammation and hypercoagulability in Here we identified platelet and monocyte activation mechanisms involved in 120 reciprocal loops of cellular communication that feed the thromboinflammatory process 121 in COVID-19. We report new mechanisms of platelet-monocyte signaling involving 122 adhesion-mediated TF expression and activity, which drives activation and 123 proinflammatory cytokine secretion in monocytes. We stablish signaling pathways 124 linking coagulation and inflammation in severe COVID-19 by identifying novel 125 mechanisms of thromboinflammation associated with severity and mortality in critically 126 ill patients. 

We prospectively enrolled a cohort of 68 RT-PCR confirmed mild (n = 22) to severe (n 132 = 46) COVID-19 patients and 25 SARS-CoV-2-negative control subjects. Blood was 133 obtained from the 46 patients with severe COVID-19 within 72 hours from ICU 134 admission in three reference centers (Instituto Estadual do Cérebro Paulo Niemeyer, 135 Hospital Copa Star and Leblon Campaign Hospital, all in Rio de Janeiro, Brazil) . 136

Severe COVID-19 was defined as those critically ill patients, presenting viral 137 pneumonia on computed tomography scan and requiring oxygen supplementation 138 through either a nonrebreather mask or mechanical ventilation. Twenty-two outpatients 139 presenting mild self-limiting COVID-19 syndrome were also included. All patients had 140 SARS-CoV-2 confirmed diagnostic through RT-PCR of nasal swab or tracheal 141 aspirates. Peripheral blood samples were collected from 25 SARS-CoV-2-negative 142 control volunteers. The characteristics of mild, severe and control participants are 143 presented in Table 1 . Mild and severe COVID-19 patients presented differences 144 regarding the age and the frequency of comorbidities (Table 1) , which is consistent 145 with previous reports 32-34 . Subjects of older age and chronic noncommunicable 146 diseases were also recruited in the SARS-Cov-2-negative control group to matched 147 with mild and severe COVID-19 patients, except for hypertension and diabetes ( 

Monocyte adhesion assays were performed as previously described 36 . Briefly, Lab-Tek plates were incubated overnight at 4 °C with PBS containing recombinant 167 human albumin, P-selectin (10 µg/ml) or fibrinogen (100 µg/ml) and then blocked with 168 albumin (10 mg/ml) for 4 hours at room temperature. The plates were washed twice 169 with PBS containing 0.05 % Tween-20 and three times with PBS. Monocytes (1 x 10 5 ) 170 from severe COVID-19 patients or control subjects were resuspended in 100 µL of 171 M199 containing 10 mg/ml polymyxin B, plated on the coated surfaces and incubated 172 overnight at 37 °C in a 5 % CO 2 atmosphere. After 12 hours post-plating, the 173 supernatants were harvested, centrifuged to remove loose cells (500 x g for 15 min) 174 and stored for further quantification of inflammatory mediators. Adherent cells were 175 fixed with 4 % paraformaldehyde and the nuclei were stained with DAPI (1 µg/mL) and 176 analyzed by fluorescence microscopy. To examine whether platelets from COVID-19 patients modulate thromboinflammatory 180 responses in monocytes from healthy volunteers, purified platelets and monocytes 181 were incubated ex vivo at 37 °C in a 5% CO 2 atmosphere. Each experimental point 182 contained 2 x 10 5 monocytes from a COVID-19 patient with 2 x 10 7 platelets from a 183 healthy volunteer, or 2 x 10 5 monocytes from a healthy volunteer with 2 x 10 7 platelets 184 from a COVID-19 patient. Control monocytes plus platelets from a different healthy 185 volunteer were used as control. In selected experiments, platelet-monocyte interactions 186

were performed in the presence of neutralizing antibodies against P-selectin (BBA30, 187 R&D Systems) (20 µg/mL), TF (clone 10H10 or 5G9) (50 µg/mL), the anti-integrin α IIb β 3 188 monoclonal antibody abciximab (50 µg/mL), or isotype-matched IgG (50 µg/mL). Eagle′s Medium supplemented with 2% fetal bovine serum at 37˚C in 5% CO 2 205 atmosphere. Virus titers were determined by the tissue culture infectious dose at 50% 206 (TCID50/mL) and the virus stocks kept in -80˚C freezers until use. All procedures 207

involving SARS-CoV-2 culture were performed in a biosafety level 3 (BSL3) facility. 208

Platelets (2 x 10 7 ) and monocytes (2 x 10 5 ) were infected with SARS-CoV-2 separately 209 or in combination (multiplicity of infection = 0.01 virus per monocyte). In selected 210 experiments, platelet-monocyte co-cultures were infected in the presence of abciximab, 211

anti-TF antibodies (clone 10H10 or 5G9), or isotype-matched IgG (50 µg/mL), or the 212 PAR-1 inhibitor SCH79797 (5 µM, Tocris 1592), PAR-2 inhibitor AZ3451 (10 µM, 213

Sigma SML2050) or DMSO (vehicle). After 12 h of infection, supernatants were 214 harvested and stored for future analysis, and cells were fixed with 4 % 215 paraformaldehyde for flow cytometry analysis as described in supplemental material. 216 217

Statistics were performed using GraphPad Prism software version 7. All the numerical 219 variables were tested regarding their distribution using the Shapiro-Wilk test. One-way 220 analysis of variance (ANOVA) was used to compare differences among 3 or more 221 groups following a normal (parametric) distribution, and Tukey's post-hoc test was used 222 to locate the differences between the groups. Comparisons between 2 groups were 223 performed using the Student t-test for parametric distributions or the Mann-Whitney U 224 test for nonparametric distributions. Considering the relationship between monocyte immunoinflammatory phenotype and 247 interaction with platelets in severe COVID-19 (Figure 1 A-B) , we investigated the 248 expression of monocyte adhesion molecules that mediate platelet-leukocyte aggregate 249

formation. Single cell RNA analysis has shown that the fibrinogen receptor Mac-1 250 subunits integrin α M (ITGAM) and integrin β 2 (ITGB2) transcripts are increased in 251 monocytes from severe COVID-19 patients ( Figure 1C and Supplemental Figure S2 ). 252

We confirmed through flow cytometry that Integrin α M (CD11b) expression is increased 253 on monocytes from severe COVID-19 patients compared to patients with mild COVID-254 19 or control subjects ( Figure 1D ), indicating increased Mac-1 expression. Importantly, 255

Mac-1 expression was higher in mechanically ventilated patients compared to patients 256 under noninvasive oxygen supplementation (Figure 1E) , and in patients that evolved 257

with mortality compared to hospital discharge ( Figure 1F) . 258

To gain insights on how monocytes from severe COVID-19 patients respond to 259 the molecules that mediate platelet-monocyte aggregate formation, we performed 260 monocyte adhesion assays on P-selectin or fibrinogen coated surfaces. As expected, 261 monocytes from healthy volunteers showed increased adhesion to recombinant P-262 selectin and fibrinogen when compared to recombinant human albumin (Figure 2A) . 263

Monocytes from severe COVID-19 patients, on the other hand, were more adhesive 264 and secreted higher levels of IL-6, IL-10 and MCP-1/CCL2 regardless of the surface on 265 which they were adhered ( We have recently shown that activated platelets from severe COVID-19 patients induce 276 monocyte TF expression 26 . We hypothesized that besides procoagulant pathways, 277 platelet-monocyte interaction also orchestrates inflammation in COVID-19. To confirm 278 this hypothesis, we incubated monocytes from healthy volunteers with platelets from 279 severe COVID-19 patients ex vivo (Figure 3A) , and evaluated the kinetics of monocyte 280 TF and CD16 expression. Platelets from severe COVID-19 patients rapidly formed 281 aggregates with control monocytes and induced TF expression up to 2 hours post-282 interaction, as compared to platelets from heterologous healthy volunteers (gray and 283 red lines in Figure 3B -C). The interaction with platelets from severe COVID-19 patients 284 also increased CD16 expression on control monocytes, even though at a later time-285 point ( Figure 3D) . 286

As previously reported, monocytes from severe COVID-19 patients present 287

increased aggregation with platelets and higher TF expression at baseline (white 288 symbols in Figure 3B -C) 26 . Interestingly, when monocytes from severe COVID-19 289 patients were exposed to platelets from healthy volunteers, platelet-monocyte 290 aggregates formation and TF expression were further enhanced (black lines in Figure  291 Previous studies from our group and others have demonstrated the ability of activated 303 platelets to regulate monocyte transcription and secretion of inflammatory 304 mediators 36,38-40 . To characterize the pattern of inflammatory mediator secretion by 305 platelet-monocyte aggregates in COVID-19, monocytes from healthy volunteers were 306 exposed to platelets from severe COVID-19 patients or platelets from a different 307 healthy volunteer. Monocytes from severe COVID-19 patients were also incubated with 308 platelets from control participants ( Figure 4A ). The levels of cytokines and eicosanoids 309

were quantified at 18-hours post-interaction. As shown in Figure 4A -C and 310

Supplemental Figure S4A , increased secretion of the proinflammatory cytokines TNF-311 α, IL-1β and IL-8/CXCL8 was observed in monocytes from healthy volunteers that 312 interacted with platelets from severe COVID-19 patients, but not with control platelets. 313

Furthermore, monocytes from healthy volunteers exposed to platelets from COVID-19 314 patients, or monocytes from COVID-19 patients exposed to platelets from healthy 315 volunteers secreted heightened levels of IL-10 and PGE 2 , which was not observed 316 when control monocytes were exposed to control platelets ( Figure 4D-E CoV-2 significantly increased platelet activation and secretion of granule-stored factors 330 ( Figure 5B-C) . Importantly, the conjunct cytokines secreted by monocytes incubated in 331 the presence of platelets showed increased diversity compared to monocytes infected 332 alone ( Figure 5D ). While monocytes exposed to SARS-CoV-2 alone enhanced the presence of platelets also displayed increased CD16 and TF expression as compared 338

to monocytes alone ( Figure 5D ). HLA-DR downregulation was a monocyte response to 339 SARS-CoV-2 independent on the presence of platelets ( Figure 5D ). These data 340 highlight platelet recognition and response to SARS-CoV-2 and platelet ability to 341 reprogram monocyte responses to virus. 342 343

An important step of our investigation was to examine whether platelet-monocyte 345 interaction could also impact on the secretion of platelet-derived mediators. 346

Interestingly, the secretion of PDGF, PF4 and TXB 2 , mediators produced exclusively by 347 platelets, was increased when platelets from healthy volunteers interacted with 348 monocytes from severe COVID-19 patients or from different control subjects ( Figure  349 4H-I and Supplemental Figure S4D ). Platelets from COVID-19 patients were also 350 responsive to the interaction with monocytes from healthy volunteers by releasing 351 PF4/CXCL4 and PDGF, as compared to platelets alone (Figure 4H-I) . Similarly, 352 platelets exposed to SARS-CoV-2 in vitro in the presence of monocytes secreted 353 higher levels of PF4/CXCL4, sCD62P, PDGF and RANTES/CCL5 than platelets 354 exposed to SARS-CoV-2 only (Figure 5 E-F) . Comparable results were observed with 355 platelets from healthy volunteers stimulated with thrombin in vitro (Supplemental 356 We have recently shown that P-selectin and integrin α IIb /β 3 play major roles in platelet-364 induced TF expression in monocytes in severe COVID-19 26 . Besides its roles in 365 coagulation, monocyte TF expression and activity have been implicated in 366 inflammatory cytokine production and immune activation 18 . Considering the earlier 367 kinetics of platelet-induced TF compared to CD16 expression on monocytes ( Figure  368 3), we hypothesized that platelet-induced TF expression might contribute to monocyte 369 inflammatory responses during platelet-monocyte aggregate formation. To investigate 370 whether TF is involved on platelet-monocyte signaling, we performed ex vivo platelet-371 monocyte coculture in the presence of a neutralizing anti-P-selectin antibody, the anti-372 α IIb /β 3 abciximab, and a pair of isotype-matched antibodies against distinct epitopes of 373 TF that impair TF direct signaling (clone 10H10) or coagulation activation (clone 374 5G9) 41 . In addition, we performed ex vivo platelet-monocyte interaction in the presence 375 of the anti-platelet drugs aspirin and clopidogrel. As shown in Figure 6A , we identified 376 patterns of platelet-induced monocyte activation depending not only on P-selectin-and 377 integrin α IIb /β 3 -mediated adhesion, but also on TF activity, leading to increased CD16 378 expression and TNF-α and IL-1β secretion ( Figure 6A) . We have also identified 379 platelet-mediated monocyte responses depending only on P-selectin-and integrin 380 α IIb /β 3 , regardless of TF activity, leading to the secretion of IL-10, IL-8/CXCL8, MIP-381 1α/CCL3 and MCP-1/CCL2 (Figure 6A and Supplemental Figure 6 ). Even though 382 aspirin treatment effectively inhibited platelet TXA 2 synthesis and PF4 secretion, aspirin 383 or clopidogrel were both unable to impair platelet-induced monocyte activation and 384 secretion ( Figure 6B -C and Supplemental Figure S7) . Importantly, the secretion of 385 the platelet-derived mediators PDGF, basic FGF and HGF were inhibited by anti-P-386 selectin and/or abciximab (Figure 6A) , reassuring the notion that platelet-monocyte 387 adhesion reciprocally signals to platelets, activating platelet secretion. 388

We then investigated whether Ixolaris, a small molecule from the saliva of the 389 tick Ixodes scapularis that blocks TF coagulant and signaling activities 18,42 , also inhibit 390 monocyte activation during platelet-monocyte aggregate formation. Exposure of control 391 monocytes to platelets from severe COVID-19 patients in the presence of Ixolaris 392 significantly impaired platelet-induced CD16 expression ( Figure 6C ). In addition, 393 treatment with Ixolaris completely blunted P-selectin-or fibrinogen-induced TNF-α 394 secretion in monocytes from severe COVID-19 patients (Figure 6D) , while the 395 secretion of MIP-1α, MIP-1β and G-CSF was enhanced (Supplemental Figure S8) . 396 397

Finally, we investigated TF-mediated platelet-monocyte signaling in response to 400 SARS-CoV-2 infection in vitro. Similar to monocytes exposed to platelets from COVID-401 19 patients, TF expression in response to SARS-CoV-2 was dependent on integrin-402 mediated platelet adhesion ( Figure 7A ). Enhanced expression of CD16, TNF-α and IL-403 1β in platelet-monocyte cocultures were dependent on both integrin α IIb /β 3 and TF-404 dependent signaling, while MCP-1/CCL2 secretion depended only on integrin signaling 405 but not TF activity ( Figure 7B) . The secretion of the platelet-derived mediators PDGF 406 and sCD62P was also inhibited by blocking the integrin α IIb /β 3 and TF coagulation 407 activity with anti-TF 5G9 clone ( Figure 7B) . To gain insights on the mechanisms of TF-408 mediated signaling in platelet-monocyte interaction, we exposed platelet-monocyte co-409 cultures to SARS-CoV-2 in the presence of the PAR1 and PAR2 selective inhibitors 410 SCH79797 and AZ3451, respectively. As shown in Figure 7C , monocyte activation and 411 proinflammatory cytokine secretion depended majorly on PAR1, while CD16 412 expression and IL-1β secretion also dependent on PAR2 activation. Importantly, PAR-1 413 inhibition also reduced platelet-monocyte aggregate formation (CD41+ monocytes), 414 PDGF and sCD62P secretion, indicating a role in platelet activation ( Figure 7C) . 415

Collectively, these data dissect novel pathways of platelet-delivered proinflammatory 416 signaling to monocytes through P-selectin-and integrin α IIb /β 3 , that amplifies platelet 417 and monocyte activation by driving TF expression and signaling through PAR1 and 2 418 ( Figure 7D) . integrin Mac-1 heterodimer, a fibrinogen receptor that participates in platelet-monocyte 448 aggregate formation 16 . These monocyte phenotypic changes may explain the 449 increased affinity to platelets and higher responsiveness to P-selectin and fibrinogen 450 during severe COVID-19, leading to TF expression and proinflammatory cytokines 451

While monocytes from severe COVID-19 patients are highly responsive to 453 platelets, the platelet activation status in COVID-19 also contributes to interaction with 454 monocytes leading to TF expression and inflammatory activation. We and others have 455 previously reported the ability of activated platelets to modulate monocyte 456 secretion 36,38-40 . We have demonstrated beforehand that platelet-monocyte aggregates 457 formation reprogram monocyte cytokine production in dengue 36,40 . We now report 458 similar results in monocytes interacting with platelets in SARS-CoV-2 infection, except 459 for a more proinflammatory profile marked by higher levels of TNF-α and IL-1β. 460

Interestingly, differential signaling was required for the secretion of distinct cytokines 461 and chemokines in this model. Platelet adhesion through P-selectin and integrin α IIb /β 3 462 is a primary signal for the secretion of a wide range of mediators, including pro-and 463 anti-inflammatory cytokines and chemokines and monocyte TF expression. TF, in its 464 turn, signals to foster monocyte CD16 expression and pro-inflammatory cytokine 465 production through PAR1 and PAR2 activation. TF-dependent PAR1 signaling was 466 also involved in platelet activation during platelet-monocyte aggregate formation 467 ( Figure 7D ). In addition to platelet-monocyte interaction, proinflammatory factors may 468 also contribute to hyperinflammation and hypercoagulability, including in driving TF 469 expression in monocytes 17,18 . Our data describe complex mechanisms of platelet-470 monocyte interaction that depend on contact-mediated signaling and are amplified by 471 TF-driven inflammatory signaling. 472

The mechanisms underlying platelet activation in severe are not yet 473 completely understood. Our data demonstrate that platelets are responsive to SARS-474

CoV-2 in vitro, even though to a lower extent compared to platelets from COVID-19 475 patients. Of note, SARS-CoV-2 RNA, proteins and virions have been detected in 476 platelets from infected patients, indicating the feasibility of SARS-CoV-2-induced 477 platelet activation in natural infections 53-55 . Previous studies have described that 478 exposure to SARS-CoV-2 activates platelets in vitro 56,57 , which may involve canonical 479 interaction through ACE-2 56,58 , but also alternative receptors as CD42 and CD147 58-60 . 480 Similar to previously reported observations 61,62 , monocytes were also responsive to 481 SARS-CoV-2 in vitro in the present work. Importantly, our experiments revealed that 482 monocytes infected together with platelets display amplified inflammatory activation 483 and secrete higher levels of inflammatory cytokines. Reports from our group and others 484 have indicated that the inflammatory mediators in COVID-19 patients' plasma also 485 activate platelets 26,28,63 . In whole blood from healthy volunteers reconstituted with 486 COVID-19 plasma, IL-6 receptor blocking by tocilizumab inhibits platelet activation, 487 platelet-leukocyte aggregates formation and TF expression 28 . Therefore, viral and 488 inflammatory factors clearly contribute to platelet activation, which in turns amplifies 489 inflammation in COVID-19 by reprogramming monocyte responses. We show that 490 platelet-monocyte interaction activates both platelets and monocytes through 491 mechanisms requiring TF-mediated PAR1 and 2 signaling, feeding hyperinflammation 492 and hypercoagulability in a reciprocal amplification loop. 493

In summary, we describe a monocyte proinflammatory program depending on Dots represent mean ± standard error of 4-6 platelet and monocyte combinations from 572 COVID-19 patients or control participants. All experiments were repeated with cells 573 from at least 2 independent control participants exposed to platelets or monocytes from 574 the same COVID-19 patients with similar results, and a representative data from one of 575 the donors is shown. # indicates p < 0.05 compared to baseline; * indicates p < 0.05 576 compared to control monocytes exposed to control platelets. represent mean ± standard error of the mean of 6-12 platelet and monocyte 587 combinations from COVID-19 patients or control participants. All experiments were 588 repeated with cells from 2 independent control participants exposed to platelets or 589 monocytes from the same COVID-19 patients with similar results, and a representative 590 data from one of the donors is shown. * indicates p < 0.05 between selected groups. Platelet-monocyte cocultures were exposed to SARS-CoV-2 overnight in the presence 636 the PAR1 inhibitor SCH79797, the PAR2 inhibitor AZ3451 or DMSO (vehicle). The 637 percent inhibition on platelet-monocyte aggregate formation, monocyte CD16 638 expression and cytokine release from platelets and monocytes is shown for each 639 condition. (D) Schematic representation of platelet-monocyte signaling through P-640 selectin and integrin α IIb /β 3 surface interaction and TF-mediated inflammatory 641 amplification through PAR1 and PAR2 during severe COVID-19. 642 

Abnormal coagulation parameters are associated 652 with poor prognosis in patients with novel coronavirus pneumonia

Incidence of thrombotic 655 complications in critically ill ICU patients with COVID-19

Incidence of venous 658 thromboembolism in hospitalized patients with COVID-19

Deep Vein Thrombosis in Hospitalized Patients 661 with COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome

Immunothrombotic dysregulation in COVID-664 19 pneumonia is associated with respiratory failure and coagulopathy

Neutrophil extracellular traps contribute 667 to immunothrombosis in COVID-19 acute respiratory distress syndrome

Thrombosis, and Angiogenesis in Covid-19

Vascular neutrophilic inflammation and 673 immunothrombosis distinguish severe COVID-19 from influenza pneumonia

Anticoagulant treatment is 676 associated with decreased mortality in severe coronavirus disease 2019 patients 677 with coagulopathy

In vitro hypercoagulability and 680 ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on 681 anticoagulation

Effect of Intermediate-Dose vs 684

Standard-Dose Prophylactic Anticoagulation on Thrombotic Events

Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients 686 with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION 687

Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet 694 pathogenic factors differ in severity of disease and sex

Clinical course and risk factors for mortality of adult 697 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

D-dimer levels on admission to predict in-hospital 700 mortality in patients with Covid-19

Leukocyte integrin Mac-1 regulates thrombosis via 703 interaction with platelet GPIbα

COVID-19 cytokine storm: the interplay between 706 inflammation and coagulation

Inflammatory monocytes expressing 709 tissue factor drive SIV and HIV coagulopathy

Platelets as Central Actors in Thrombosis -Reprising 712 an Old Role and Defining a New Character

Circulating platelets as 715 mediators of immunity, inflammation, and thrombosis

Amicus or adversary 718 revisited: Platelets in acute lung injury and acute respiratory distress syndrome

Innate immune receptors in 721 platelets and platelet-leukocyte interactions

Nouvelle Cuisine: Platelets Served 724 with Inflammation

Platelets and the immune continuum

Role of CD40 and ADAMTS13 in von Willebrand 729 factor-mediated endothelial cell-platelet-monocyte interaction

Platelet activation and 732 platelet-monocyte aggregate formation trigger tissue factor expression in 733 patients with severe COVID-19

Platelet gene expression and 736 function in patients with COVID-19

Potential Mechanisms Behind the Thrombotic Complications of COVID-19

Platelets Promote Thromboinflammation in 743

Complement and tissue 746 factor-enriched neutrophil extracellular traps are key drivers in COVID-19

Tissue Factor: An Essential Mediator of Hemostasis 750 and Trigger of Thrombosis

Cardiovascular Implications of Fatal Outcomes of 753

Patients with Coronavirus Disease

Risk Factors Associated With Acute Respiratory 756

Distress Syndrome and Death in Patients With Coronavirus Disease

Association of Cardiac Injury with Mortality in 760

Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol

Global outbreak research: harmony not 763 hegemony

Platelet Activation 766 and Apoptosis Modulate Monocyte Inflammatory Responses in Dengue

Activation in Patients With Symptomatic Peripheral Artery Disease

Activated platelets signal chemokine 775 synthesis by human monocytes

Dengue virus-activated platelets 778 modulate monocyte immunometabolic response through lipid droplet biogenesis 779 and cytokine signaling

Disulfide isomerization switches tissue 782 factor from coagulation to cell signaling

inhibitor Ixolaris prevents tissue factor signaling on tumor cells

Incidence, characteristics and 788 outcomes of patients with severe community acquired-MRSA pneumonia

Diagnostic 791 and prognostic values of admission procalcitonin levels in community-acquired 792 pneumonia in an intensive care unit

Haematological manifestations in patients with 795 severe acute respiratory syndrome: Retrospective analysis

Coinfection with Staphylococcus aureus 798 increases risk of severe coagulopathy in critically ill children with influenza A 799 (H1N1) virus infection

Pathological 802 evidence of pulmonary thrombotic phenomena in severe COVID-19

Vascular Disease and Thrombosis in 805

SARS-CoV-2-Infected Rhesus Macaques

A Descriptive 808 and Quantitative Immunohistochemical Study Demonstrating a Spectrum of 809

Platelet Recruitment Patterns Across Pulmonary Infections Including COVID-19

Severe COVID-19 is characterized by the 815 co-occurrence of moderate cytokine inflammation and severe monocyte 816 dysregulation

Single-cell multi-omics analysis of 818 the immune response in COVID-19

Platelets Can Associate with SARS-CoV-2 RNA 821 and Are Hyperactivated in COVID-19

Platelets contribute to disease severity in COVID-19

SARS-CoV-2 Initiates Programmed Cell Death in 826

SARS-CoV-2 binds platelet ACE2 to enhance 829 thrombosis in COVID-19

SARS-CoV-2 interacts with platelets and megakaryocytes via 832

ACE2-independent mechanism

SARS-CoV-2 Initiates Programmed 835

Unconventional CD147-dependent 838 platelet activation elicited by SARS-CoV-2 in COVID-19

Platelets mediate inflammatory monocyte activation by 841

SARS-CoV-2 spike protein

SARS-CoV-2 843 engages inflammasome and pyroptosis in human primary monocytes

CoV-2 replication and production of inflammatory mediators

Association of Neutrophil Activation

Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 850 2019